(Fighting against New Coronary Pneumonia) South African company claims to have developed Africa's first mRNA new crown vaccine
China News Agency, Johannesburg, February 4 (Reporter Wang Xi) On February 4, local time in South Africa, according to South African mainstream media reports, South Africa's Afrigen Biologics and Vaccines Company (Afrigen) has successfully developed the first drug on the African continent. mRNA (messenger ribonucleic acid) new coronary pneumonia vaccine, which will be officially put into clinical trials in November this year.
Since the outbreak of COVID-19 in South Africa in March 2020, South African Avergan Biologics and Vaccines, headquartered in Cape Town, South Africa, has been committed to the development and production of localized vaccines in South Africa.
Its scientific research work has been supported by the World Health Organization and the "New Coronary Pneumonia Vaccine Implementation Plan" and other parties, so that certain technological innovations have been carried out on the basis of the Moderna vaccine, and the first African mRNA new coronary pneumonia vaccine has been successfully developed.
Animal testing of the vaccine will begin in March this year, while clinical trials are expected to begin around November, according to Avergan.
Once all tests are passed, the vaccine will be officially put into the fight against the epidemic in South Africa and the African continent.
It is worth mentioning that, unlike traditional vaccines that need to be stored in a low temperature environment, this mRNA new coronary pneumonia vaccine can adapt to normal temperature environments and is easier to store.
(Finish)